A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2018

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms UNCOVER-1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2018 Results of an exposure-response analysis from UNCOVER-1, UNCOVER-2, and UNCOVER-3 studies, published in the Journal of Clinical Pharmacology.
    • 17 Mar 2018 Results of post hoc analysis of three trials (NCT01474512 (UNCOVER-1), NCT01597245 (UNCOVER-2), and NCT01646177 (UNCOVER-3).) summarizing he 12-week efficacy and safety data of Ixekizumab published in the Journal of the American Academy of Dermatology
    • 13 Mar 2018 Results assessing impact of Ixekizumab treatment on cardiovascular related parameters using Patient data from UNCOVER-1, 2, 3 trials published in the Journal of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top